



option care health®  
INFUSION THERAPY + PHARMACY SERVICES

# Broad Access to Immunoglobulin (IG) Therapies

As the largest independent infusion services provider in the U.S.<sup>1</sup>, Option Care Health meets the comprehensive needs of autoimmune patients. Our extraordinary team of highly skilled professionals are committed to quality and exceptional patient care.

- **Extensive payer coverage**
  - o 96%<sup>2</sup> coverage to insured lives
- **Clinical pharmacy appeals team, supporting all IG claims**
- **Patient assistance program expertise**
  - o Our integrated system matches eligible patients with manufacturer copay assistance and foundation programs coupled with an expedited income verification process, reducing insurance approval time
- **Flexible infusion therapy settings and the largest infusion therapy nursing network**
  - o Patient's Home | Infusion Suite | 170+<sup>2</sup> nationwide locations

**Immunoglobulin Therapy**

# One simple choice for extraordinary infusion care

- **Only national infusion provider in-network with every national health plan including their affiliates<sup>1</sup>**
  - o National | Regional | Medicare | Medicaid
- **Treat a wide range of acute and chronic conditions through our comprehensive infusion portfolio**
  - o Clinically managing 95,000+<sup>1</sup> IG infusions each year
- **Transitioning patient's onto care quickly**
  - o Dedicated patient intake reduces administrative burdens
- **93%<sup>2</sup> patient satisfaction rating**

References: 1. Data on file, Option Care. 2. January-March 2024 patient satisfaction data.

## Multiple brands of IG therapies for personalized care

	Intravenous/Subcutaneous		
Product	Gammagard® Liquid	Gammaked™	Gamunex®-C
Manufacturer	Takeda Pharmaceutical Company Limited 800.828.2088 takeda.com gammagard.com	Kedrion Biopharma, Inc. 855.353.7466 kedrion.us gammaked.com	Grifols 888.694.2686 grifols.com gamunex-c.com
Indications	PI (adults & peds 2+ yrs.) MMN (adults, maintenance therapy) CIDP (adult)	PI (adults & peds 2+ yrs.) ITP (adults & children) CIDP (adults)	PI (adults & peds 2+ yrs.) ITP (adults & children) CIDP (adults)
Contraindications	IgA deficiency with antibodies to IgA; history of anaphylactic or severe systemic reactions to IG therapy	IgA deficiency with antibodies to IgA; history of anaphylactic or severe systemic reactions to IG therapy	IgA deficiency with antibodies to IgA; history of anaphylactic or severe systemic reactions to IG therapy
Form	Liquid	Liquid	Liquid
Concentration	10%	10%	10%
Sizes	1/2.5/5/10/20/30 g	1/2.5/5/10/20 g	1/2.5/5/10/20/40 g
Virus removal method	Cohn-Oncley cold ethanol fractionation, cation/anion exchange chromatography, solvent/detergent, nanofiltration, low pH incubation	Cold ethanol fractionation, caprylate precipitation/filtration, anion exchange chromatography, low pH incubation	Cold ethanol fractionation, caprylate precipitation/filtration, anion exchange chromatography, low pH incubation
IgA content	37 µg/mL	46 µg/mL	46 µg/mL
Stabilizer	Glycine	Glycine	Glycine
Sugar content	None	None	None
Sodium content	None	Unspecified	Unspecified
pH	4.6-5.1	4.0-4.5	4.0-4.5
Osmolality (mOsmol/kg)	240-300	258	258
Half-life (days)	31-42	35.7	35.7
Administration	<b>PI/MMN:</b> <b>IV:</b> Begin at 0.8 mg/kg/min for first 30 minutes, if tolerated, gradually increase every 30 minutes to maximum infusion rate of 8 mg/kg/min. (MMN: May advance to 9 mg/kg/min as tolerated). <b>PI:</b> <b>SubQ:</b> Begin 1 week after last IVIG dose. (≥ 40kg) begin with 30 mL/site @ 20 mL/hr/site; maintenance 30 mL/site @ 20-30 mL/hr/site. (< 40kg) begin with 20 mL/site @ 15 mL/hr/site; maintenance 20 mL/site @ 15-20 mL/hr/site.	<b>PI/ITP:</b> <b>IV:</b> Begin at 1 mg/kg/min for first 30 minutes, if tolerated, gradually increase to maximum infusion rate of 8 mg/kg/min. <b>CIDP:</b> <b>IV:</b> Begin at 2 mg/kg/min for first 30 minutes, if tolerated, gradually increase to maximum infusion rate of 8 mg/kg/min. <b>PI:</b> <b>SubQ:</b> Begin 1 week after last IVIG dose. (adults) infuse @ 20 mL/hr/site; (children/adolescents ≥ 25kg) initially infuse @ 15 mL/hr/site; maintenance @ 20 mL/hr/site; (children/adolescents < 25kg) infuse @ 10 mL/hr/site.	<b>PI/ITP:</b> <b>IV:</b> Begin at 1 mg/kg/min for first 30 minutes, if tolerated, gradually increase to maximum infusion rate of 8 mg/kg/min. <b>CIDP:</b> <b>IV:</b> Begin at 2 mg/kg/min for first 30 minutes, if tolerated, gradually increase to maximum infusion rate of 8 mg/kg/min. <b>PI:</b> <b>SubQ:</b> Begin 1 week after last IVIG dose. (adults) infuse @ 20 mL/hr/site; (children/adolescents ≥ 25kg) initially infuse @ 15 mL/hr/site; maintenance @ 20 mL/hr/site; (children/adolescents < 25kg) infuse @ 10 mL/hr/site.
Shelf-life/storage requirements	Refrigerated 2 to 8°C [36 to 46°F] for 36 months OR room temperature up to 25°C [77°F] for 24 months	Refrigerated 2 to 8°C [36 to 46°F] for 36 months OR room temperature up to 25°C [77°F] for 6 months	Refrigerated 2 to 8°C [36 to 46°F] for 36 months OR room temperature up to 25°C [77°F] for 6 months

# Multiple brands of IG therapies for personalized care

## Intravenous

Product	Panzyga®	Gammaplex®	Octagam®	Privigen®	Bivigam®	Asceniv®	Alyglo®	Gammagard® S/D Low IgA
<b>Manufacturer</b>	Octapharma USA, Inc. 866.766.4860 octapharmausa.com panzyga.info	Bio Products Laboratory Limited 866.398.0825 bpl.us.com gammaplex.com	Octapharma USA, Inc. 866.766.4860 octapharmausa.com octagamus.net	CSL Behring AG 800.504.5434 cslbehring.com privigen.com	ADMA Biologics 800.458.4244 admabiologics.com bivigam.com	ADMA Biologics 800.458.4244 admabiologics.com asceniv.com	GC Biopharma 833.426.6426 gcbiopharma.us alyglo.com	Takeda Pharmaceutical Company Limited 800.828.2088 takeda.com
<b>Indications</b>	PI (adults & peds 2+ yrs.) Chronic ITP (adults)	5% - PI (adults & peds 2+ yrs.); Chronic ITP 10% - PI (adults); Chronic ITP (adults)	5% - PI 10% - Chronic ITP (adults)	PI Chronic ITP (15+ yrs.) CIDP (adults)	Indicated for the treatment of adults and pediatric patients 2+ yrs with primary humoral immunodeficiency	Indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age)	Indicated for the treatment of primary humoral immunodeficiency (PI) in adults	PI CLL Chronic ITP Kawasaki syndrome
<b>Contraindications</b>	IgA deficiency with antibodies to IgA & history of sensitivity; history of anaphylactic or severe systemic reactions to IG therapy	IgA deficiency with antibodies to IgA & history of sensitivity; hereditary intolerance to fructose; history of anaphylactic or severe systemic reactions to IG therapy	IgA deficiency with antibodies to IgA; history of anaphylactic or severe systemic reactions to IG therapy; hypersensitivity to corn (5%)	IgA deficiency with antibodies to IgA; history of anaphylactic or severe systemic reactions to IG therapy; hyperproliferemia	History of anaphylactic or severe systemic reactions to human immunoglobulin; IgA deficient patients with antibodies to IgA and a history of hypersensitivity	History of anaphylactic or severe systemic reactions to human immunoglobulin; IgA-deficient patients with antibodies to IgA and a history of hypersensitivity	History of anaphylactic or severe systemic reactions to human immunoglobulin; gA-deficient patients with antibodies against IgA or a history of hypersensitivity	IgA deficiency with antibodies to IgA; history of anaphylactic or severe systemic reactions to IG therapy
<b>Form</b>	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Lyophilized
<b>Concentration</b>	10%	5/10%	5/10%	10%	10%	10%	10%	5/10%
<b>Sizes</b>	1/2.5/5/10/20/30 g	5/10/20 g	5%: 1/2.5/5/10/25 g 10%: 2/5/10/20/30 g	5/10/20/40 g	5/10 g	5 g	5/10/20 g	2.5/5/10 g
<b>Virus removal method</b>	Cold ethanol fractionation, solvent/detergent, ion exchange chromatography, nanofiltration	Solvent/detergent, nanofiltration, low pH incubation, cold ethanol fractionation, ion exchange chromatography	Cold ethanol fractionation, solvent/detergent, pH incubation, ultrafiltration, ion exchange chromatography	Cold ethanol fractionation, octanoic acid fractionation, anion exchange chromatography, immunoaffinity chromatography	Cold ethanol fractionation, solvent/detergent treatment, and 35nm virus filtration.	Cold ethanol fractionation, solvent/detergent treatment, and 35nm virus filtration.	Fractionation I/III, solvent/detergent treatment, and Nanofiltration	Cold ethanol fractionation, ultrafiltration, ion exchange chromatography, solvent/detergent
<b>IgA content</b>	100 µg/mL	5%: < 10 µg/mL 10%: < 20 µg/mL	5%: ≤ 200 µg/mL 10%: 106 µg/mL	≤ 25 µg/mL	≤ 200 µg/mL of IgA	≤ 200 µg/mL of IgA	≤ 100 mcg/mL of IgA	<1 µg/mL
<b>Stabilizer</b>	Glycine	5%: D-sorbitol, glycine, polysorbate 80 10%: glycine, polysorbate 80	Maltose	L-proline	Glycine	Glycine	Glycine	Albumin (human), glycine, glucose, PEG, tri-n-butyl phosphate, octoxynol, polysorbate 80
<b>Sugar content</b>	None	5%: D-sorbitol (no sucrose) 10%: None	Maltose (no sucrose)	None	None	None	None	20 mg/mL glucose
<b>Sodium content</b>	Trace	5%: 30-50 mmol/L 10%: < 30mmol/L	≤30 mmol/L	Trace	0.100-0.140 M sodium chloride	0.100-0.140 M sodium chloride	Unspecified	5%: approx 8.5 mg/mL
<b>pH</b>	4.5-5.0	5%: 4.8-5.1 10%: 4.9-5.2	5%: 5.1-6.0 10%: 4.5-5.0	4.6-5.0	4.0-4.6	4.0-4.6	4.5-5.5	6.8±0.4
<b>Osmolality (mOsmol/kg)</b>	240-310	5%: 420-500 10%: 280	310-380	240-440	370-510	370-510	Unspecified	Unspecified
<b>Half-life (days)</b>	26-39	41-42	40.7	27.6-45.4	30	39.7 ± 11.6	29.6 ± 11	37.7±15
<b>Administration</b>	<b>IV:</b> Begin at 1 mg/kg/min for the first 30 minutes; if tolerated, gradually increase every 15-30 minutes to maximum infusion rate of 8 mg/kg/min. New patients or ITP treatment, up to a maximum infusion rate of 12 or 14 mg/kg/min for experienced IVIG patients.	<b>5% infusion rate:</b> <b>IV:</b> Begin at 0.5 mg/kg/min for first 15 minutes; if tolerated, gradually increase every 15 minutes to maximum infusion rate of 4 mg/kg/min. <b>10% infusion rate:</b> <b>IV:</b> Begin at 0.5 mg/kg/min for first 15 minutes; if tolerated, gradually increase every 15 minutes to maximum infusion rate of 8 mg/kg/min.	<b>5% infusion rate:</b> <b>IV:</b> Begin at 0.5 mg/kg/min for first 30 minutes; if tolerated, gradually increase to maximum infusion rate of 3.33 mg/kg/min. <b>10% infusion rate:</b> <b>IV:</b> Begin at 1 mg/kg/min for first 30 minutes; if tolerated, gradually increase to maximum infusion rate of 12 mg/kg/min.	<b>PI/CIDP:</b> <b>IV:</b> Begin at 0.5 mg/kg/min; if tolerated, gradually increase to maximum infusion rate of 8 mg/kg/min. <b>ITP:</b> <b>IV:</b> Begin at 0.5 mg/kg/min; if tolerated, gradually increase to maximum infusion rate of 4 mg/kg/min.	<b>IV:</b> Begin at 0.5 mg/kg/min (0.005 mL/kg/min) for first 10 min, Increase every 20 minutes (if tolerated) by 0.8 mg/kg/min up to 6 mg/kg/min	<b>IV:</b> Begin at 0.5 mg/kg/min (0.005 mL/kg/min) for the first 15 minutes, Increase gradually every 15 minutes (if tolerated) up to 8 mg/kg/min (0.08 mL/kg/min)	<b>IV:</b> 1st Infusion: Begin at 1 mg/kg/min; Double the infusion rate every 30 minutes (if tolerated) up to 8 mg/kg/min (0.08 mL/kg/min) 2nd Infusion: Begin at 2 mg/kg/min; Double the infusion rate every 15 minutes (if tolerated) up to 8 mg/kg/min (0.08 mL/kg/min)	<b>5% infusion rate:</b> <b>IV:</b> Begin at 0.5 mL/kg/hr, if tolerated, gradually increase to maximum infusion rate of 4 mL/kg/hr. <b>10% infusion rate:</b> <b>IV:</b> Patient who tolerates the 5% concentration can infuse 10% solution; begin at 0.5 mL/kg/hr, if tolerated gradually increase to maximum infusion rate of 8 mL/kg/hr.
<b>Shelf-life/storage requirements</b>	Refrigerated 2 to 8°C [36 to 46°F] for 24 months from date of manufacture; within shelf-life, may store at ≤ 25°C [77°F] for up to 9 months. After storage at ≤ 25°C [77°F], either use immediately or discard	<b>5/10%:</b> Room temperature at 2 to 25°C [36 to 77°F] for up to 36 months	<b>5%:</b> Room temperature at 2 to 25°C [36 to 77°F] for up to 24 months <b>10%:</b> Refrigerated 2 to 8°C [36 to 46°F] for 24 months from date of manufacture; room temperature up to 9 months at ≤ 25°C [77°F] within first 12 months of shelf-life	Room temperature up to 25°C [77°F] for 36 months	Store at 2° to 8°C (36° to 46°F) for up to 36 months from date of manufacture. Within the first 24 months of shelf-life, product may be stored up to 4 weeks at ≤ 25°C (77°F). After 24 months, product may be stored at ≤ 25°C up to 2 weeks, until expiry. After storage at room temperature product must be used or discarded.	Store at 2°-8°C (36°-46°F) for up to 36 months from date of manufacture. Within the first 24 months of shelf-life, product may be stored up to 4 weeks at ≤ 25° C (77° F). After 24 months, product may be stored at ≤ 25°C up to 2 weeks, until expiry. After storage at room temperature, product must be used or discarded.	Store ALYGLO in the refrigerator or at room temperature. Refrigeration: 2°C to 8°C [36°F to 46°F] for up to 36 months. Room Temperature: 8°C to 25°C [46°F to 77°F] for up to 24 months.	Room temperature; not to exceed 25°C [77°F]

## Multiple brands of IG therapies for personalized care

	Subcutaneous				
Product	Cutaquig®	Hizentra®	Xembify®	Cuvitru®	HyQvia®
Manufacturer	Octapharma USA, Inc. 866.766.4860 octapharmausa.com cutaquigus.com	CSL Behring AG 800.504.5434 cslbehring.com hizentra.com	Grifols 888.694.2686 grifols.com xembify.com	Takeda Pharmaceutical Company Limited 800.828.2088 takeda.com cuvitru.com	Takeda Pharmaceutical Company Limited 800.828.2088 takeda.com hyqvia.com
Indications	PI (adults)	PI (adults & peds 2+ yrs.) CIDP (adults; maintenance therapy)	PI (adults & peds 2+ yrs.)	PI (adults & peds 2+ yrs.)	PI (adults & peds 2+ yrs.) CIDP (adults)
Contraindications	IgA deficiency with antibodies to IgA & history of sensitivity; history of anaphylactic or severe systemic reactions to IG therapy	IgA deficiency with antibodies to IgA; history of anaphylactic or severe systemic reactions to IG therapy or components of Hizentra; hyperproliferemia	IgA deficiency with antibodies to IgA; history of anaphylactic or severe systemic reactions to IG therapy or inactive ingredients such as polysorbate 80	IgA deficiency with antibodies to IgA; history of anaphylactic or severe systemic reactions to IG therapy	IgA deficiency with antibodies to IgA; history of anaphylactic or severe systemic reactions to IG therapy; known systemic hypersensitivity to hyaluronidase and albumin (human)
Form	Liquid	Liquid	Liquid	Liquid	Liquid
Concentration	16.5%	20%	20%	20%	10%
Sizes	1/1.65/2/3.3/4/8 g	1/2/4/10 g	1/2/4/10 g	1/2/4/8/10 g	2.5/5/10/20/30 g
Virus removal method	Cold ethanol fractionation, solvent/ detergent, pH incubation, ultrafiltration, ion exchange chromatography	Cold ethanol fractionation, octanoic acid fractionation, anion exchange chromatography, pH incubation, nanofiltration	Cold ethanol fractionation, caprylate precipitation/filtration, anion exchange chromatography, low pH incubation	Cohn-Oncley cold fractionation, cation/anion exchange chromatography, solvent/detergent, nanofiltration, low pH incubation	Cohn-Oncley cold ethanol fractionation, cation/anion exchange chromatography, solvent/detergent, nanofiltration, low pH incubation
IgA content	≤600 µg/mL	≤50 µg/mL	≤70 µg/mL	80 µg/mL	37 µg/mL
Stabilizer	Maltose	L-proline, polysorbate 80	Glycine, polysorbate 80	Glycine	Glycine
Sugar content	Maltose (no sucrose)	None	None	None	None
Sodium content	≤30 mmol/L	Trace	Trace	None	Recombinant human hyaluronidase component: 8.5 mg/mL sodium chloride 1.78 mg/mL sodium phosphate 0.17 mg/mL sodium hydroxide IG component: None
pH	5-5.5	4.6-5.2	4.1 to 4.8	4.6-5.1	Recombinant human hyaluronidase component: 7.4 IG component: 4.6-5.1
Osmolality (mOsmol/kg)	310-380	210-290	280-404	280-292	Recombinant human hyaluronidase component: 290-350 IG component: 240-300
Half-life (days)	Unspecified	Unspecified	Unspecified	Unspecified	50-68.6
Administration	<b>PI:</b> <b>SubQ:</b> Begin 1 week after last IVIG dose; first 6 infusions @ ≤25 mL/site @ ≤20 mL/hr/site; maintenance ≤40 mL/site @ ≤25 mL/hr/site.	<b>PI:</b> <b>SubQ:</b> Begin 1-2 weeks after last IVIG dose, depending on dosing frequency. Initial 15 mL/site @ 15 mL/hr/site; maintenance 25 mL/site @ 25 mL/hr/site. <b>CIDP:</b> <b>SubQ:</b> Begin 1-2 weeks after last IVIG dose, depending on dosing frequency. Initial 20 mL/site @ 20 mL/hr/site; maintenance 50 mL/site @ 50 mL/hr/site.	<b>PI:</b> <b>SubQ:</b> Begin 1 week after last IVIG dose; ≤25 mL/site @ ≤25 mL/hr/site; max sites ≤6; site distance administered ≥2 inches apart.	<b>PI:</b> <b>SubQ:</b> Begin 1 week after last IVIG dose; (≥40kg) first 2 infusions @ ≤60 mL/site @ 10-20 mL/hr/site; maintenance ≤60 mL/site @ ≤60 mL/hr/site; (<40kg) first 2 infusions @ ≤20 mL/site @ 10-20 mL/hr/site; maintenance ≤60 mL/site @ ≤60 mL/hr/site.	<b>PI:</b> <b>SubQ:</b> Begin 1 week after last IVIG dose; administer recombinant human hyaluronidase at initial rate/site @ 1-2 mL/min as tolerated. (≥40kg) administer up to 600 mL/site @ rates as shown in table 3 of package insert; (<40kg) administer up to 300 mL/site @ rates as shown in table 3 of package insert.
Shelf-life/storage requirements	Refrigerated 2 to 8°C [36 to 46°F] for 24 months from date of manufacture OR room temperature up to 25°C [77°F] for 6 months during its shelf-life	Room temperature up to 25°C [77°F] for 30 months	Refrigerated 2 to 8°C [36 to 46°F] OR room temperature up to 25°C [77°F] for 6 months	Room temperature up to 25°C [77°F] for 12 months OR refrigerated 2 to 8°C [36 to 46°F] for up to 36 months	Refrigerated 2 to 8°C [36 to 46°F] for 36 months OR room temperature up to 25°C [77°F] for 3 months during the first 24 months from date of manufacture

“ I have a team of people who have embraced my journey, and will take that journey with me. ”

- Kara, Option Care Health CVID patient



See how Kara, regained her independence and joy with the help of Option Care Health's infusion therapy services. Scan the QR code to watch her inspiring story.

# Contact Option Care Health to Refer a Patient!

---

Phone: 877.974.4844

Fax: 877.974.4845

[optioncarehealth.com](https://optioncarehealth.com)



option care health®

INFUSION THERAPY + PHARMACY SERVICES